Bank of New York Mellon’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $60.8M | Buy |
163,610
+14,303
| +10% | +$4.27M | 0.01% | 944 |
|
|
2026
Q1 | $38.6M | Sell |
149,307
-2,006
| -1% | -$534K | 0.01% | 1149 |
|
|
2025
Q4 | $37.3M | Sell |
151,313
-4,240
| -3% | -$892K | 0.01% | 1180 |
|
|
2025
Q3 | $27.5M | Sell |
155,553
-4,964
| -3% | -$743K | ﹤0.01% | 1363 |
|
|
2025
Q2 | $22.1M | Sell |
160,517
-8,662
| -5% | -$1.27M | ﹤0.01% | 1467 |
|
|
2025
Q1 | $30.5M | Sell |
169,179
-167
| -0.1% | -$28.1K | 0.01% | 1266 |
|
|
2024
Q4 | $26.5M | Sell |
169,346
-2,307
| -1% | -$409K | ﹤0.01% | 1394 |
|
|
2024
Q3 | $31.2M | Sell |
171,653
-22,114
| -11% | -$4.26M | 0.01% | 1314 |
|
|
2024
Q2 | $35.6M | Buy |
193,767
+103,928
| +116% | +$17.4M | 0.01% | 1229 |
|
|
2024
Q1 | $16M | Sell |
89,839
-8,812
| -9% | -$1.22M | ﹤0.01% | 1705 |
|
|
2023
Q4 | $12.2M | Buy |
98,651
+431
| +0.4% | +$47.8K | ﹤0.01% | 1866 |
|
|
2023
Q3 | $11.4M | Buy |
98,220
+1,604
| +2% | +$196K | ﹤0.01% | 1870 |
|
|
2023
Q2 | $11.3M | Buy |
96,616
+17,053
| +21% | +$1.74M | ﹤0.01% | 1884 |
|
|
2023
Q1 | $6.37M | Sell |
79,563
-2,533
| -3% | -$199K | ﹤0.01% | 2164 |
|
|
2022
Q4 | $6.5M | Sell |
82,096
-2,696
| -3% | -$200K | ﹤0.01% | 2181 |
|
|
2022
Q3 | $5.91M | Buy |
84,792
+4,529
| +6% | +$327K | ﹤0.01% | 2205 |
|
|
2022
Q2 | $5.27M | Sell |
80,263
-6,632
| -8% | -$413K | ﹤0.01% | 2265 |
|
|
2022
Q1 | $5.78M | Buy |
86,895
+3,444
| +4% | +$215K | ﹤0.01% | 2341 |
|
|
2021
Q4 | $5.84M | Buy |
83,451
+7,022
| +9% | +$409K | ﹤0.01% | 2380 |
|
|
2021
Q3 | $3.99M | Buy |
76,429
+5,799
| +8% | +$343K | ﹤0.01% | 2596 |
|
|
2021
Q2 | $4.8M | Buy |
70,630
+3,262
| +5% | +$228K | ﹤0.01% | 2516 |
|
|
2021
Q1 | $5.19M | Sell |
67,368
-112
| -0.2% | -$8.14K | ﹤0.01% | 2437 |
|
|
2020
Q4 | $4.05M | Buy |
67,480
+5,065
| +8% | +$253K | ﹤0.01% | 2455 |
|
|
2020
Q3 | $2.69M | Buy |
62,415
+3,502
| +6% | +$152K | ﹤0.01% | 2511 |
|
|
2020
Q2 | $2.44M | Sell |
58,913
-6,307
| -10% | -$303K | ﹤0.01% | 2562 |
|
|
2020
Q1 | $2.82M | Sell |
65,220
-2,369
| -4% | -$124K | ﹤0.01% | 2363 |
|
|
2019
Q4 | $3.74M | Sell |
67,589
-5,027
| -7% | -$247K | ﹤0.01% | 2483 |
|
|
2019
Q3 | $2.52M | Buy |
72,616
+7,890
| +12% | +$353K | ﹤0.01% | 2630 |
|
|
2019
Q2 | $2.61M | Buy |
64,726
+43,859
| +210% | +$1.43M | ﹤0.01% | 2663 |
|
|
2019
Q1 | $687K | Sell |
20,867
-3,810
| -15% | -$89.8K | ﹤0.01% | 3396 |
|
|
2018
Q4 | $513K | Buy |
+24,677
| New | +$517K | ﹤0.01% | 3466 |
|
Other funds holding KRYS
SCM
Bank of New York Mellon's KRYS Position: Q2 2026 in Review
Bank of New York Mellon increased its Krystal Biotech (KRYS) stake by 9.6% in Q2 2026, buying an estimated $4.27M and bringing the position to 163,610 shares worth $60.8M. The position accounts for 0.01% of the portfolio, ranked #944.
Bank of New York Mellon first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. 261 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Bank of New York Mellon held 163,610 shares of Krystal Biotech worth $60.8M as of Q2 2026.
- Bank of New York Mellon bought 14,303 Krystal Biotech shares in Q2 2026, an estimated $4.27M.
- Krystal Biotech made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #944 holding.
- Bank of New York Mellon first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
- 261 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.